Newsroom
Pr Aristocort®C now available in a 50g tube
Effective immediately, Valeo Pharma is pleased to announce the introduction of a new format for Aristocort®C Cream 0.5%. As of February 22, 2010, the topical corticosteroid is available in a 50g tube in addition to the original 15g tube format.
Aristocort®C is indicated for topical therapy of corticosteroid responsive acute and chronic dermatoses, where an anti-inflammatory, anti-allergenic and antipuritic activity in topical management is required.
Valeo Pharma announces Richard J. Mackay as Chairman
Montreal, Quebec - January 14, 2010
Steve Saviuk, President and CEO of Valeo Pharma, is pleased to announce the appointment of Mr. Richard J. (Dick) MacKay to the position of Chairman of Valeo Pharma. Mr. MacKay joins Valeo Pharma following his retirement from Stiefel, where he held the positions of Vice-Chairman of the Board of Directors of Stiefel Laboratories, and President of Stiefel Canada. Mr. MacKay was instrumental in establishing Stiefel in Canada as well as in global markets; the company is recognized worldwide as the leader in dermatologicals.
In a career that spans over a half century in the Canadian pharmaceutical industry and dermatology business, Mr. MacKay brings a wealth of experience and achievement to Valeo Pharma. Richard MacKay's experience in building strategic alliances and developing business in the Canadian dermatology market will be of great benefit to Valeo Pharma. Valeo Pharma, established in 2003, is committed to providing health care professionals and patients with high quality specialty pharmaceutical products.
These products include Aristocort, Valisone Scalp Lotion, Hydrosal Gel, Clinda-T, and Valisone-G.
U.S. Study Shows Significant Improvements for Patients
Suffering from Excessive Sweating with Topical Antiperspirant
Patients report higher quality of life as a result from using of Hydrosal in just a few months
Albany, New York (May, 2009) Valeo Pharma announced today a new study recently published that demonstrated the efficacy and safety of Hydrosal®, a novel high strength topical antiperspirant with 15% aluminum chloride and 2% salicylic acid in proprietary gel base for patients with moderate-to-severe hyperhidrosis (excessive sweating).
The study, conducted by Katherine Flanagan, MD and Dee Anna Glaser, MD at the Department of Dermatology at Saint Louis University School of Medicine, was published in the May issue of the Journal of Drugs in Dermatology (JDD). Of the thirty patients who were enrolled, 43% had tried high-strength antiperspirants previously. Patients were given Hydrosal and monitored at 4 and 12 weeks for efficacy and tolerability. They were instructed to apply a small amount of the gel at bedtime for seven days and twice per week or as tolerated thereafter.
Overall, 70% of participants demonstrated significant improvements in satisfaction of treatment and was well-tolerated with minimal side effects. Patients who had previously failed other high-strength antiperspirants also reported similar success in treatment with Hydrosal. They also experienced significant improvements in quality of life; such as improvement in social situations and effectiveness at work.
“The key to Hydrosal's success is the gel base – this is what makes it different, with a balance of high efficacy and tolerability for patients with moderate to severe hyperhidrosis. Valeo is most thrilled that these results have shown a significant improvement in the quality of life for these patients, so they can enjoy activities more and not have to worry about their excessive sweating,” stated Dean Michelin, Executive Vice President of Commercial Operations for Valeo Pharma.